Lido Advisors
COGT icon

Lido Advisors’s Cogent Biosciences COGT Stock Holding History

Lido Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Sell
8,496
-665
-7% -$23.3K ﹤0.01% 1715
2026
Q1 		$353K Buy
+9,161
New +$338K ﹤0.01% 1482

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lido Advisors's COGT Position: Q2 2026 in Review

Lido Advisors reduced its Cogent Biosciences (COGT) stake by 7.3% in Q2 2026, selling an estimated $23.3K and leaving 8,496 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #1715.

Lido Advisors first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. The position peaked at $353K in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Lido Advisors held 8,496 shares of Cogent Biosciences worth $329K as of Q2 2026.
  • Lido Advisors sold 665 Cogent Biosciences shares in Q2 2026, an estimated $23.3K.
  • Cogent Biosciences made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1715 holding.
  • Lido Advisors first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Lido Advisors's Cogent Biosciences position peaked at $353K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.